Status:
UNKNOWN
Autoimmune Cytopenia and BcR Inhibitors
Lead Sponsor:
Institut Paoli-Calmettes
Collaborating Sponsors:
CHU de Reims
Conditions:
Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)
Detailed Description
The investigators of the study propose a card of data collection, validated by the scientific council of the group FILO. The data to be collected are entered on an e-CRF made available to the investi...
Eligibility Criteria
Inclusion
- Patient with CLL
- Active autoimmune cytopenia
- Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.
Exclusion
- Other lymphoid hemopathy B
- Absence of documentation of the autoimmunity of cytopenia
Key Trial Info
Start Date :
July 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03469895
Start Date
July 21 2017
End Date
July 1 2018
Last Update
March 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Paoli Calmettes
Marseille, Bouches Du Rhone, France, 13009